[go: up one dir, main page]

ZA200907137B - Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain - Google Patents

Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain

Info

Publication number
ZA200907137B
ZA200907137B ZA200907137A ZA200907137A ZA200907137B ZA 200907137 B ZA200907137 B ZA 200907137B ZA 200907137 A ZA200907137 A ZA 200907137A ZA 200907137 A ZA200907137 A ZA 200907137A ZA 200907137 B ZA200907137 B ZA 200907137B
Authority
ZA
South Africa
Prior art keywords
heteroaryltetrahydronaphtalene
heteroarylchromane
pain
novel
treatment
Prior art date
Application number
ZA200907137A
Other languages
English (en)
Inventor
Yevgeni Besidski
Inger Kers
Martin Nyloef
Lars Sandberg
Karin Skogholm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200907137(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200907137B publication Critical patent/ZA200907137B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200907137A 2007-04-23 2009-10-13 Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ZA200907137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
ZA200907137B true ZA200907137B (en) 2010-07-28

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907137A ZA200907137B (en) 2007-04-23 2009-10-13 Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain

Country Status (23)

Country Link
US (2) US8143408B2 (xx)
EP (1) EP2158198B1 (xx)
JP (1) JP2010525056A (xx)
KR (1) KR20100015827A (xx)
CN (1) CN101687860B (xx)
AR (1) AR066266A1 (xx)
AU (1) AU2008241610B2 (xx)
BR (1) BRPI0810354A2 (xx)
CA (1) CA2685141A1 (xx)
CL (1) CL2008001170A1 (xx)
CO (1) CO6251361A2 (xx)
EC (1) ECSP099706A (xx)
IL (1) IL201309A0 (xx)
MX (1) MX2009011364A (xx)
MY (1) MY146662A (xx)
NZ (1) NZ581353A (xx)
PE (1) PE20090727A1 (xx)
RU (1) RU2460730C2 (xx)
SA (1) SA08290245B1 (xx)
TW (1) TW200848037A (xx)
UY (1) UY31046A1 (xx)
WO (1) WO2008130320A2 (xx)
ZA (1) ZA200907137B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP3725775A1 (en) 2009-02-17 2020-10-21 Syntrix Biosystems, Inc. Pyridine- and pyrimidinecarboxamides as cxcr2 modulators
CN106117213B (zh) * 2009-10-26 2022-03-18 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法
UA103272C2 (xx) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2$2-амино-5,5-дифтор-5,6-дигидро-4h-оксазины как ингибиторы bace1 и/или bace2
WO2011093501A1 (ja) 2010-02-01 2011-08-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
EP2608672B1 (en) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
EP2951168B1 (en) * 2013-01-31 2017-01-04 Vertex Pharmaceuticals Incorporated Quinoline and quinoxaline amides as modulators of sodium channels
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
MX2016010056A (es) * 2014-02-06 2016-11-15 Abbvie Inc 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
MY194015A (en) 2015-11-13 2022-11-08 Daewoong Pharmaceutical Co Ltd Sodium channel blocker
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
KR20200020911A (ko) * 2017-06-30 2020-02-26 바이엘 애니멀 헬스 게엠베하 새로운 아자퀴놀린 유도체
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3851436B1 (en) 2018-09-10 2024-06-12 Kaken Pharmaceutical Co., Ltd. Novel heteroaromatic amide derivative and medicine containing same
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
NZ545710A (en) 2003-08-08 2010-02-26 Vertex Pharma Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
WO2006119451A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
JP2009542803A (ja) * 2006-07-12 2009-12-03 アストラゼネカ・アクチエボラーグ 鎮痛剤としての３−オキソイソインドリン−１−カルボキサミド誘導体
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Also Published As

Publication number Publication date
IL201309A0 (en) 2010-05-31
SA08290245B1 (ar) 2012-02-12
PE20090727A1 (es) 2009-07-23
EP2158198B1 (en) 2013-03-20
CO6251361A2 (es) 2011-02-21
KR20100015827A (ko) 2010-02-12
RU2009138137A (ru) 2011-05-27
AU2008241610B2 (en) 2011-08-18
AU2008241610A1 (en) 2008-10-30
WO2008130320A3 (en) 2008-12-18
NZ581353A (en) 2012-02-24
MX2009011364A (es) 2009-11-05
WO2008130320A2 (en) 2008-10-30
US8143408B2 (en) 2012-03-27
AR066266A1 (es) 2009-08-05
CN101687860A (zh) 2010-03-31
MY146662A (en) 2012-09-14
CL2008001170A1 (es) 2009-05-22
EP2158198A4 (en) 2012-01-04
UY31046A1 (es) 2008-11-28
US20100137322A1 (en) 2010-06-03
EP2158198A2 (en) 2010-03-03
CA2685141A1 (en) 2008-10-30
BRPI0810354A2 (pt) 2014-10-21
TW200848037A (en) 2008-12-16
ECSP099706A (es) 2009-11-30
JP2010525056A (ja) 2010-07-22
US20120238579A1 (en) 2012-09-20
RU2460730C2 (ru) 2012-09-10
CN101687860B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
IL201309A0 (en) Novel n - (8 - heteroaryltetrahydronaphtalene - 2yl) or n - (5 - heteroarylchromane - 3 - yl) carboxamide derivatives for the treatment of pain
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
GB0610867D0 (en) Treatment of pain
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
ZA200706868B (en) 4-Oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases
IL193748A0 (en) Treatment of pain
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL218143A0 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
GB0909297D0 (en) Composition for the treatment of skin conditions
PT2323644E (pt) Derivados de benzenopropanamida ou benzenopropenamida, substituídos em n, com utilização no tratamento da dor
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
IL194798A0 (en) Treatment of melanoma
GB0610868D0 (en) Treatment of pain
HK1141791A (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
GB0616450D0 (en) Treatment of pain
ZA200708853B (en) Methods of treatment utilizing certain melatonin derivatives
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
GB0604772D0 (en) Use of substituted amine compounds for the treatment of food related disorders